Ethan H. Rubinstein - Publications

In vitro evaluation of the effect of linezolid and levofloxacin on Bacillus anthracis toxin production, spore formation and cell growth.

Journal: The Journal of antimicrobial chemotherapy

Published: May 03, 2016

Alternative pre-approved and novel therapies for the treatment of anthrax.

Journal: BMC infectious diseases

Published: February 26, 2016

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Journal: Drugs

Published: February 13, 2015

Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 05, 2014

Bacteremia caused by Eggerthella lenta in an elderly man with a gastrointestinal malignancy: A case report.

Journal: The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

Published: November 06, 2014

Prone positioning decreases cardiac output and increases systemic vascular resistance in neonates.

Journal: Journal of perinatology : official journal of the California Perinatal Association

Published: August 28, 2014

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia.

Journal: Infection and drug resistance

Published: May 31, 2014

Comparison between transthoracic and transesophageal echocardiography in screening for infective endocarditis in patients with Staphylococcus aureus bacteremia.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: April 14, 2014

Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.

Journal: Emerging infectious diseases

Published: January 23, 2014

Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.

Journal: Antimicrobial agents and chemotherapy

Published: January 15, 2014

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.

Journal: The Journal of antimicrobial chemotherapy

Published: January 09, 2014

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Journal: Drugs

Published: December 20, 2013